Artwork

Content provided by BBC and BBC World Service. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BBC and BBC World Service or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

The weight-loss drug revolution

17:28
 
Share
 

Manage episode 422296108 series 1897284
Content provided by BBC and BBC World Service. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BBC and BBC World Service or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?

Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.

Presented by Leanna Byrne and produced by Lexy O'Connor

(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)

  continue reading

1948 episodes

Artwork

The weight-loss drug revolution

Business Daily

1,111 subscribers

published

iconShare
 
Manage episode 422296108 series 1897284
Content provided by BBC and BBC World Service. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BBC and BBC World Service or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of Mounjaro. But with competitors desperate for a piece of the action, how long can these two giants stay in front?

Leanna Byrne hears from some of the companies involved, including those at the centre of the action and those developing the next wave of treatments.

Presented by Leanna Byrne and produced by Lexy O'Connor

(Image: A box of the anti-obesity drug Wegovy, including injection pens. Credit: Getty Images)

  continue reading

1948 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide